Use of aldosterone antagonists to inhibit myocardial fibrosis

Details Use of aldosterone antagonists to inhibit myocardial fibrosis Use of aldosterone antagonists to inhibit myocardial fibrosis

1999-03-22

2000-07-25

Cook, Rebecca

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514173, A61K 31585

Patent

active

060937084

ABSTRACT:
This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).

REFERENCES:
Brilla et al, J. Hypertension 8(3), 1990.
Remington's Pharmaceutical Sciences, 15th Ed., pp. 867-868, 1975.

Affiliated with

Also associated with

Rating

Use of aldosterone antagonists to inhibit myocardial fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of aldosterone antagonists to inhibit myocardial fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aldosterone antagonists to inhibit myocardial fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1336721